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The contribution of peripheral immunity to autism spectrum disorders (ASDs) risk is debated and poorly understood. Some
mothers of children with ASD have autoantibodies that react to fetal brain proteins, raising the possibility that a subset of ASD
cases may be associated with a maternal antibody response during gestation. The mechanism by which the maternal immune
system breaks tolerance has not been addressed. We hypothesized that the mechanism may involve decreased expression of
the MET receptor tyrosine kinase, an ASD risk gene that also serves as a key negative regulator of immune responsiveness. In a
sample of 365 mothers, including 202 mothers of children with ASD, the functional MET promoter variant rs1858830 C allele was
strongly associated with the presence of an ASD-speciﬁc 37þ73-kDa band pattern of maternal autoantibodies to fetal brain
proteins (P¼0.003). To determine the mechanism of this genetic association, we measured MET protein and cytokine
production in freshly prepared peripheral blood mononuclear cells from 76 mothers of ASD and typically developing children.
The MET rs1858830 C allele was signiﬁcantly associated with MET protein expression (P¼0.025). Moreover, decreased
expression of the regulatory cytokine IL-10 was associated with both the MET gene C allele (P¼0.001) and reduced MET protein
levels (P¼0.002). These results indicate genetic distinction among mothers who produce ASD-associated antibodies to fetal
brain proteins, and suggest a potential mechanism for how a genetically determined decrease in MET protein production may
lead to a reduction in immune regulation.
Translational Psychiatry (2011) 1, e48; doi:10.1038/tp.2011.48; published online 18 October 2011
Introduction
Autism spectrum disorders (ASDs) are a complex, behavio-
rally deﬁned group of developmental disorders characterized
by social deﬁcits, language impairments and repetitive
behaviors with restricted interests. Previous studies of twins
andsiblingrecurrenceriskhavesuggestedthatASDisamong
the most heritable of neuropsychiatric disorders, encouraging
extensive research into the genetic basis of ASD risk.
1–3
However, a more recent twin study reported that susceptibility
toASDhasamuchlowergeneticheritabilitycomponent,while
the more substantial component of risk was explained by
environmental factors in a shared twin environment.
4 This
would indicate that the gestational environment, susceptible
to genetic regulation by both the fetus and the mother, might
be a major factor in determining ASD risk. The genetic risk
may lie in (a) the direct impact of genetic regulation on brain
development, (b) altering sensitivities to environmental
factors and (c) disruption of autonomic and peripheral organ
development and function that may inﬂuence brain develop-
ment. In this regard, there is a growing body of evidence that,
among risk factors, immune system dysregulation may be a
feature in this neurodevelopmental disorder.
5–7
Growing evidenceindicates thatmaternal immune dysfunc-
tion during gestation may contribute to ASD risk. In animal
models, maternal immune activation during gestation leads to
behavioral changes in subsequent offspring.
8 In humans,
epidemiologic analyses reported that a family history of
autoimmune disorders was more common in families of
children with ASD,
9,10 and that immune-mediated disorders
(psoriasis, maternal asthma and allergy) occurred more often
around the time of pregnancy in the mothers of children with
ASD compared with the mothers with typically developing
(TD) children.
11 One early report demonstrated that serum
from a mother of a child with ASD showed IgG antibody
reactivity to rodent Purkinje cells; this same serum was then
injected into gestating mice and shown to elicit behavioral
deﬁcits in the offspring.
12 In another study, 11 mothers of
children with ASD and their affected children were found to
have consistent patterns of antibody reactivity against rat
prenatal brain proteins.
13 Further studies have highlighted
that this reactivity is to fetal and not adult brain proteins.
14 Our
recent studies have demonstrated reactivity against fetal
brain proteins at B37 and 73kDa in plasma from 7 of 61
(11.5%) mothers of children with ASD but not in 102 mothers
of TD children.
15 Injection of rhesus monkeys with human IgG
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www.nature.com/tpfrom mothers of children with ASD (who were positive for fetal
brain antibodies) during gestation resulted in increased
stereotypical behavior and hyperactivity in the offspring when
compared with the offspring of rhesus monkeys injected with
IgG from mothers of TD children.
16 Evidence of a potential
role for these antibodies with respect to changes in
neurodevelopment was also noted in a recent murine
model.
17
Although the preponderance of evidence points to an
immune-mediated etiology in some cases of ASD, the
biological mechanism of the maternal immune dysfunction
remains unclear. In an independent line of study, we
described robust genetic association with ASD of a functional
variant in the 50 promoter of the gene encoding the MET
receptor tyrosine kinase.
18 The MET promoter variant,
rs1858830,isacommonG-to-Csingle-nucleotidepolymorph-
ism (SNP); the ‘C’ allele is inherited by individuals with ASD
more often than predicted by chance and is more common in
individuals with ASD than in a sample of the general
population.
18–20 Stratifying ASD subpopulations demon-
strated that association of the MET ‘C’ allele is enriched in
individuals with co-occurring ASD and gastrointestinal condi-
tions,
21 and in the social and communication domains of
ASD.
22 Independent evidence indicates decreased expres-
sion of the ligand for the MET receptor, hepatocyte growth
factor (HGF), in serum of individuals with co-occurring ASD
and gastrointestinal conditions.
23 In addition to its roles in
brain development and gastrointestinal repair, the MET
receptortyrosinekinaseisakeynegativeregulatorofimmune
responsiveness. Ligation of the MET receptor by its HGF
ligand prevents lupus nephritis in chronic graft-versus-host
disease,
24 ameliorates the progression of experimental
autoimmune myocarditis
25 and suppresses collagen-induced
arthritis in mice.
26 MET also induces morphogenic changes in
antigen-presenting cells. Importantly, MET signaling induces
a tolerogenic phenotype in antigen-presenting cells through
the induction of IL-10, without affecting their antigen-present-
ing capabilities.
27,28 This tolerogenic phenotype induces
T regulatory cells in response to antigen that would otherwise
have broken tolerance and potentially lead to autoimmunity.
28
MET protein expression is decreased in postmortem brain of
individuals with the MET ‘C’ allele.
29 If the same genotype–
expression correlation is observed in the immune system,
then one prediction is that disrupted MET signaling may
confer susceptibility to immune dysregulation. We hypothe-
sized that MET disruption would be associated with markers
of immune dysregulation in mothers of children with ASD. To
test this hypothesis, we examined the MET promoter variant
rs1858830 ‘C’ allele in the context of ASD-speciﬁc maternal
antibodiestofetalbrainproteins,aswellasthecytokineproﬁle
of peripheral blood cells following immune challenge.
Materials and methods
Subjects. All mothers, (n¼365) including those of children
with an ASD (n¼202) and those of TD control children
(n¼163), participated in the Childhood Autism Risks from
Genetics and the Environment (CHARGE) study.
30 Those
children enrolled in the study met the following criteria: (a)
they were between the ages of 24 and 60 months at the time
of enrollment, (b) lived with at least one biologic parent, (c)
had a parent who spoke either English or Spanish, (d) were
born in the state of California and (e) resided in the
catchment areas of a speciﬁed list of regional centers in
Northern California. The CHARGE study is an ongoing
population-based case–control study. This study protocol
followed the ethical guidelines of the most recent Declaration
of Helsinki, and was approved by the institutional review
boards at the University of California, Davis, The State of
California Department of Developmental Services, and the
University of Southern California. Informed consent was
obtained before participation.
To conﬁrm the initial diagnosis, all children enrolled in the
study were assessed at the UC Davis M.I.N.D. Institute. The
diagnosis of ASD was conﬁrmed in all subjects using the
standardized Autism Diagnostic Interview–Revised (ADI–
R)
31 and the Autism Diagnostic Observation Schedule
(ADOS) modules 1 or 2.
32–35 The ADI–R provides a
standardized, semi-structured interview and a diagnostic
algorithmfortheDSM-IV
36andICD-10deﬁnitionsofautism.
37
All of the CHARGE study clinical assessment personnel have
attained research reliability on the ADI–R and the ADOS. The
Social Communication Questionnaire was used to screen for
behavioral and developmental characteristics of ASD among
TD controls; children who scored above the screening cutoff
score of 15 were fully assessed using the ADI–R and ADOS.
Those controls that met criteria for autistic disorder were
classiﬁed as ASD. Controls who did not meet criteria for ASD
were classiﬁed as TD.
Autoantibodies. Western blot data collected and analyzed
in a previous study was used for the association analyses
described herein. Western blots were performed as
previously described using fetal monkey brain extract.
15,38
Genotyping the ASD-associated MET promoter variant
rs1858830. As the rs1858830 SNP falls within a highly GC-
rich region, indirect genotyping methods fail when using
genomic DNA. A 652-bp fragment containing the rs1858830
SNP was ampliﬁed from 15ng genomic DNA with primers 50-
GATTTCCCTCTGGGTGGTG-30 (Forward) and 50-CAAGC
CCCATTCTAGTTTCG-30 (Reverse). Each 20-ml reaction
included 15ng genomic DNA, 1mM each primer, 5%
dimethyl sulfoxide, 15mM MgCl2, 0.25mM each dNTP
(dATP, dCTP, dGTP and dTTP), 2.5U AmpliTaq Gold DNA
Polymerase (ABI, Carlsbad, CA, USA) and 0.2U Turbo pfu
DNA polymerase (Stratagene, Santa Clara, CA, USA).
Cycling conditions were: 951C for 5min followed by 35
cycles of 951C for 30s, 611C for 30s and 721C for 1min.
Speciﬁc ampliﬁcation of the 652-bp product was conﬁrmed
by agarose gel electrophoresis. Each PCR product was
subjected to direct re-sequencing using an ABI 3730xl using
Big Dye Terminator chemistry. Genotype at the MET
rs1858830 locus was determined from the sequencing
result using Sequencher software (Gene Codes, Ann
Arbor, MI, USA).
Cell culture and stimulation. CHARGE is an ongoing
study for which we have collected and banked both plasma
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both autoantibody production and genotype at the MET
rs1858830 locus. However, cytokine production in response
to immune challenge must be done on freshly isolated
peripheral blood mononuclear cells (PBMCs). Therefore, a
random subset of 76 mothers (22 C/C, 33 C/G and 21 G/G),
prospective to study initiation, was used to assess the
functional cytokine response in relation to MET rs1858830
genotype. Whole blood was collected through venipuncture
into yellow top citrate tubes (BD, Franklin Lakes, NJ, USA)
according to study protocol, and centrifuged at 900g for
10min to pellet cells. Plasma was collected and immediately
frozen in 0.5ml aliquots at  801C until assayed by western
blot for the presence of anti-fetal brain antibodies. The cell
pellet was then adjusted to appropriate density with HBSS
and layered over Histopaque density gradient (Sigma,
St Louis, MO, USA) followed by centrifugation at 600g for
30min. The PBMC layer was removed and washed two
additional times at 900g for 10min at which point cells were
counted with a hemocytometer, and 300000 cells per well
were plated into 96-well round bottom plates. Cells were then
allowed to rest 24h before administration of 5mgml
 1
lipopolysaccharide for 48h to induce the production of an
innate immune response. After stimulation, cell culture
supernatants and cell pellets were frozen at  801C until
assayed for cytokine levels and MET protein levels,
respectively.
Determination of cytokine levels. As a measure of innate
immune reactivity following lipopolysaccharide stimulation,
cell culture supernatants were analyzed for seven different
cytokine and chemokines, including IL-6, GM-CSF, IL-1, IL-
12p40, TNF-a, MIP-1b and IL-10. Levels were determined
using a commercially available multiplex bead-based kit and
run according to manufacturer’s instructions (Millipore,
Billerica, MA, USA). Brieﬂy, 25ml of cell culture supernatant
was incubated with anti-cytokine-conjugated beads in a 96-
well ﬁlter-bottom plate on a plate shaker overnight at 41C.
The beads were then washed using a vacuum manifold, and
biotin-conjugated detection antibodies were added for a 1-h
incubation, followed by the subsequent addition of
streptavidin-PE for 30min. The plates were then read on a
Bio-Plex 100 (BioRad, Hercules, CA, USA), and analyzed
using Bio-Plex Manager software using a 5-point standard
curve. Reference samples were run on each plate to
determine assay consistency.
Determination of MET protein levels. After the
supernatant was extracted, the cultured cells were used to
determine the expression of the membrane-bound MET
protein. The cell pellet was resuspended in 60-ml Novagen
Widescreen protein extraction reagent. Protein assays were
performed with the Luminex xMAP technology with a bead-
based MET (HGF-Receptor) ELISA kit (Novagen, Rockland,
MA, USA), by manufacturer’s protocol. Brieﬂy, the isolated
protein was mixed with capture beads containing primary
antibody directed to MET (HGF-Receptor; Novagen),
followed by overnight shaking incubation at 41C. Protein
was measured on the Bio-Plex Suspension Array System
(Bio-Rad, Hercules, CA, USA) at the Beckman Center Core
at the USC Norris Cancer Center. Data acquisition and
analysis were performed using the Bio-Plex Manager
software (Bio-Rad).
Statistical analyses. The w
2 was used to analyze the
association of MET rs1858830 genotype with the presence
of maternal antibody. Allelic w
2 results are presented; genotypic
w
2 results are similar. Genotype-dependent differences in
MET protein and cytokine production were determined by
analysis of variance followed by post-hoc Tukey–Kramer tests.
Linear regression was used to determine correlation between
MET protein expression and cytokine levels. Bonferroni
correction for multiple comparisons was used to account for
the analysis of multiple cytokines.
Results
Maternal antibody patterns associated with ASD risk. In
a previous report with the CHARGE sample,
30 association
with ASD risk was demonstrated for a 37þ73-kDa band
pattern of maternal antibodies reactive to fetal brain proteins
in 61 mothers of children with ASD but not 102 mothers of TD
children.
15 Data for the current study were derived from an
expanded study to include a total of 202 mothers of children
with an ASD and 163 mothers of TD children.
38 Speciﬁcity of
the combined 37þ73-kDa band pattern with ASD risk was
maintained in this larger sample. The 37þ73-kDa band
pattern (as illustrated in conjunction with Table 1) was
present in 19 of 202 (9%) mothers of children with an ASD,
and none of the 163 mothers of TD children (Table 1).
Association of MET rs1858830 C allele with ASD-
associated maternal antibody band patterns. We next
stratiﬁed the sample by maternal antibody patterns that have
been shown to be associated with ASD risk in the offspring,
and performed genetic association tests with the MET
rs1858830 genotype. Among the 19 mothers who were
positive for the 37þ73-kDa band pattern, 11 (58%) were
homozygous for the ASD-associated MET rs1858830 C
allele, 7 (37%) were C/G heterozygotes and one (5%) was
homozygous for the G allele (Table 2). Among the 183
mothers of children with ASD who were negative for the
37þ73-kDa band pattern, 51 (28%) were C/C homozygous,
79 (43%) were C/G heterozygous and 53 (29%) were G/G
homozygous (Table 2). This MET C allele frequency of 76%
in the 19 mothers with the 37þ73-kDa band pattern was
signiﬁcantly higher than the 49% C allele frequency observed
Table 1 Incidence of antibody reactivity to fetal brain proteins in mothers of
children with an ASD compared with mothers of TD children
Diagnosis of offspring N Positive for 37/73-kDa
band pattern (%)
ASD 202 19 (9)*
TD 163 0 (0)
ASD + TD 365 19 (5)
Abbreviations: ASD, autism spectrum disorder; TD, typically developing.
Figure (B) illustrates the 37/73-kDa band pattern by western blot where lane 1
represents an antibody-positive mother of a child with an ASD, and lane 2
represents the mother of a TD control. *Po0.0001 ASD vs TD.
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the 37þ73-kDa band pattern (P¼0.002; Table 2). Among
346 mothers of both ASD and TD children who were negative
for the 37þ73-kDa band pattern, 101 (29%) were C/C, 154
(45%) were C/G and 91 (26%) were G/G (Table 2). The 76%
frequency of the MET C allele in mothers with the 37þ73-
kDa band pattern was also signiﬁcantly higher than the 51%
C allele frequency observed in all 346 mothers lacking the
band pattern (P¼0.003; Table 2).
Association of MET rs1858830 genotype with MET
protein levels in PBMCs of nonpregnant mothers. We
previously reported an association of the MET C allele with
decreased MET protein levels in postmortem brain samples
from individuals with ASD.
29 To determine if MET rs1858830
genotype also predicts MET protein levels in peripheral
blood, we measured MET protein levels in stimulated PBMCs
isolated from 76 mothers of ASD and TD children, as MET is
only expressed on immune cells in response to activation. As
anticipated, results were similar to those observed in
postmortem brain where the expression of MET protein
was signiﬁcantly reduced. In mothers with the MET
rs1858830 C/C genotype, MET protein expression was
reduced 1.4-fold in PBMCs compared with mothers with
the G/G genotype (P¼0.030; Figure 1). MET protein was
also signiﬁcantly decreased in mothers with the C/G
genotype compared with the G/G genotype (P¼0.025;
Figure 1).
Correlation of both MET C allele and reduced MET
protein levels with decreased cytokine IL-10 production
in mothers. In the same PBMCs used for cellular MET
protein level analysis, we also measured the production of
seven cytokines (IL-1, IL-6, IL-10, IL-12(p40), GM-CSF, MIP-
1b and TNF-a) following stimulation with lipopolysaccharide
of PBMC cultures. Production of the regulatory cytokine IL-10
was signiﬁcantly associated with MET rs1858830 genotype
and MET protein levels. The production of IL-10 was
decreased 1.8-fold in mothers of genotype C/C compared
with mothers of genotype G/G (P¼0.001; Figure 2a). As
expected by the association of MET genotype to MET protein
levels, the production of IL-10 was also positively correlated
with the amount of MET protein (P¼0.002; Figure 2b). It is
important to note that the signiﬁcance of both of these results
survive Bonferroni correction for analysis of seven analytes.
The effect of MET genotype was speciﬁc to IL-10 as there
was no correlation to expression of the other six cytokines
tested.
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Figure 1 AssociationofMETrs1858830genotypewithMETproteinexpression
in peripheral blood mononuclear cells (PBMCs). MET protein expression was
reduced 1.4-fold in mothers of genotype C/C (4.7±0.7ngmg
 1 total protein)
compared with mothers of genotype G/G (6.7±0.8ngmg
 1 total protein)
(P¼0.030). MET protein expression was also decreased in mothers of genotype
C/G compared with mothers of genotype G/G (P¼0.025). There was no signiﬁcant
difference in MET protein expression between mothers of genotype C/C and C/G
(P¼0.463).
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Figure 2 Correlation of both MET rs1858830 genotype (a) and MET protein
levels (b) with IL-10 expression in peripheral blood mononuclear cells (PBMCs). (a)
IL-10 protein is increased 1.8-fold in G/G genotype mothers (2295±321ngmg
 1)
compared with C/C genotype mothers (1267±192ngmg
 1)( P¼0.001). IL-10
proteinis increased1.6-fold in G/G genotypemotherscomparedwith C/G genotype
mothers (1429±165ngmg
 1)( P¼0.005). (b) Linear regression indicates highly
signiﬁcant correlation (r¼0.401; P¼0.003) between expression of MET protein
and expression of IL-10 protein.
Table 2 Association of MET rs1858830 C allele with the ASD-associated
37+73-kDa band pattern
37/73-kDa bands N MET
C/C (%)
MET
C/G (%)
MET
G/G (%)
Allelic
v
2 P
ASD positive 19 11 (58) 7 (37) 1 (5) Reference
ASD negative 183 51 (28) 79 (43) 53 (29) 0.002
ASD + TD negative 346 101 (29) 154 (45) 91 (26) 0.003
Abbreviations: ASD, autism spectrum disorder; TD, typically developing.
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The results of this study suggest that the functional MET
promoter variant rs1858830 C allele is associated with the
presenceofASD-associatedmaternalantibodiestofetalbrain
proteins. The convergence of these two previously distinct
associations with ASD risk (that of maternal antibodies to fetal
brain proteins and of the MET C allele) provides the ﬁrst link
betweenanASD susceptibilitygeneandafunctionalimmune-
related outcome to that gene.
MET is a receptor tyrosine kinase, serving different
functions in distinct cell types, including proliferation, moto-
genesis, survival and differentiation. MET is best understood
asanoncogeneinvolvedinthemetastasis ofseveral cancers:
somatic gain-of-function mutations lead to dramatically
increased signaling via the MET receptor, and uncontrolled
cell proliferation and migration.
39 MET is also involved in
mediating HGF signaling in a number of developmental,
physiological and repair processes, including liver regenera-
tion,
40 gastrointestinal repair,
41–43and in serving asa part of a
negative feedback loop in immune responses.
27,44,45 The
MET C allele decreases transcription and results in reduced
MET receptor tyrosine kinase protein in postmortem brain
samples.
18,29
In the current study, we demonstrate that the MET C allele is
also associated with decreased expression of MET protein in
the immune system. As MET functions as a key negative
regulator of immune function, the association of a functional
genetic variant and ASD suggests a possible mechanism
through which ASD-speciﬁc maternal antibodies to fetal brain
proteins are generated. In addition to its role in autoimmunity,
theMETreceptorligandHGFhasalsobeenshowntoattenuate
inﬂammatory conditions such as acute hyper responsiveness
and airway remodeling in a murine model of asthma,
46 as well
as the suppression of acute and chronic cardiac transplant
rejection in the mouse.
47 While animal models lend support to
an immunosuppressive role, the exact mechanism by which
HGFexertsitseffectsontheimmunesystemhasnotbeenfully
elucidated. The MET receptor has been detected on mono-
cytes/macrophages, dendritic cells and B cells, but not on T
cells, even though HGF has been implicated in the adhesion
and migration of memory T cells.
27,44,48–51 Interestingly, MET
protein expression is low to undetectable in inactive cells but
increases dramatically in response to cellular activation.
44,51 In
this study, we provide evidence that subjects harboring the
MET ‘C’ allele are deﬁcient in a crucial immunoregulatory
molecule, IL-10, that may leave them more susceptible to
prolonged inﬂammatory conditions.
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Figure 3 Proposed model of the mechanism by which maternal MET genotype predisposes, via immune dysregulation, toward neurodevelopmental alterations
characteristic of ASD.
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cytokine that has been shown to be upregulated in animal
models, in which HGF is important in the prevention of
autoimmunity.
25,26,52 In addition, in vitro studies on the effects
of HGF on both human and mouse antigen-presenting cells
implicate IL-10 as a major contributor to the reported anti-
inﬂammatory effects.
28,53 IL-10 has been reported to be
decreased in children with ASD compared with controls,
54–56
butonlyinthecontextofinnatecellactivation.Inthecontextof
adaptive immune activation or at baseline, IL-10 levels in
children with ASD are unchanged.
57–61 However, there have
not been any studies investigating the potential role of IL-10
dysregulation in the mothers of children with ASD.
In this study, we describe a decrease in levels of IL-10 that
is signiﬁcantly correlated with levels of MET protein expres-
sion. We had anticipated an increase in inﬂammatory
cytokines as MET signaling has been shown to directly
modulate theinﬂammatoryresponse throughphosphorylation
of GSK3b; however, unlike other studies we did not observe a
signiﬁcant increase in pro-inﬂammatory cytokine produc-
tion.
53 This is likely attributed to both the cellular composition
ofthe stimulatedcultures (theuseofwhole PBMC inour study
vs the use of bone marrow-derived macrophages in animal
studies)aswellasthetimingofcytokinemeasurements(48vs
24h). IL-10 is most often attributed with the resolution of an
inﬂammatory response. It may be that signaling through the
MET receptor functions to shorten the duration of the
inﬂammatory response and not necessarily the magnitude,
thereby allowing sustained inﬂammation in mothers with the
MET ‘C’ allele. Such sustained inﬂammation would provide an
environment conducive to loss of tolerance, thereby increas-
ing the risk of autoantibody production, or potentiate a change
in the cytokine proﬁle during pregnancy that could negatively
affect proper neurodevelopment (Figure 3).
A limitation of this study, and of our predicted model, is the
lackofdataindicatingthefactorresponsibleforinitiationofthe
inﬂammatory response. While the MET ‘C’ allele may provide
susceptibility toward reduced immune regulation, an environ-
mental trigger such as infection, xenobiotic exposure or other
stressor is still required to initiate an immune response. This
may partially explain why the ‘C’ allele is evenly distributed
among the population but is highly prevalent in mothers who
exhibit markers of immune dysregulation, that is, autoanti-
body production. Future studies in a prospective model that
will allow for tracking of environmental insults are needed to
explore this mechanism in further detail.
Several studies have now addressed the potential role for
maternal antibodies to fetal brain proteins in ASD.
12–17,38
While each of these studies demonstrated both antibody
speciﬁcity as well as a potential pathologic signiﬁcance of the
maternal autoantibodies, the current study is the ﬁrst to
present evidence suggesting a genetic polymorphism asso-
ciated with the production of these antibodies. We fully
acknowledge that no single gene or environmental factor will
account for the entirety of ASD etiologies, and thus our focus
on one ASD candidate gene, the MET receptor tyrosine
kinase, was based on its bi-functional role in brain and
immune development. Our observations that MET rs1858830
genotype predicts MET protein expression in the immune
system, and that lower MET protein levels are correlated with
lower regulatory cytokine levels, provides mechanistic sup-
port for this focus. The studies described herein represent the
beginning of our investigation into the potential mechanism(s)
by which the maternal immune system becomes susceptible
to the generation of antibodies to fetal brain tissue. Identiﬁca-
tion of a predisposing genetic factor such as MET will
contribute greatly toward the understanding of the mechan-
isms involved in a subset of ASD cases.
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